<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480698</url>
  </required_header>
  <id_info>
    <org_study_id>EVER-AT0717</org_study_id>
    <nct_id>NCT03480698</nct_id>
  </id_info>
  <brief_title>Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness</brief_title>
  <acronym>C-REGS2</acronym>
  <official_title>C-REGS2 - A Registry Study to Observe Clinical Practices, Safety and Efficiency of Routine Use of Cerebrolysin in the Treatment of Patients With Moderate to Severe Neurological Deficits After Acute Ischaemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ever Neuro Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>idv Data Analysis and Study Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ever Neuro Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the clinical practices, safety and effectiveness of Cerebrolysin in
      routine treatment of patients with moderate to severe neurological deficits after acute
      ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients registered: Acute Ischemic Stroke patients with moderate to severe neurological
      deficits

      All patients receive acute stroke care according to local treatment standards, not amended or
      influenced by the study:

      Cerebrolysin Group:

      Patients who are treated with Cerebrolysin; dosage, frequency and duration follows local
      clinical practice in accordance with terms of the local marketing authorization

      Control group:

      Patients who are not treated with Cerebrolysin

      Observation criteria:

        -  Signed Informed Consent

        -  Clinical diagnosis of acute ischemic stroke confirmed by imaging

        -  Moderate to severe neurological deficits with NIH Stroke Scale (NIHSS) 8 to 15, both
           inclusive

        -  No prior stroke

        -  No prior disability

        -  Patient's independence prior to stroke onset (pre-morbid mRS of 0 or 1)

        -  Reasonable expectation of successful follow-up (max. 100 days)

      The study follows the recommendations of the Principles for Good Research on Comparative
      Effectiveness (GRACE).

      In order to comply with recent calls for high-quality non-interventional comparative
      effectiveness research, a risk-based centralized statistical approach to monitoring is
      introduced in combination with targeted on-site monitoring for ongoing surveillance of study
      conduct, thus ensuring highest standards of data quality and integrity according to the most
      recent requirements of the ICH E6 Guideline for Good Clinical Practice (GCP, Amendment R2,
      July 2015), the FDA Guidance for Industry on a Risk-based Approach to Monitoring, and the EMA
      reflection-paper on risk-based quality management in clinical trials.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>90 Days</target_duration>
  <primary_outcome>
    <measure>Ordinal modified Rankin Scale (mRS) at 3 months after stroke onset</measure>
    <time_frame>3 months</time_frame>
    <description>The modified Rankin Scale scale is used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ordinal NIH Stroke Scale (NIHSS) at 21 days and 3 months after stroke onset</measure>
    <time_frame>Day 21 and 3 months</time_frame>
    <description>The National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ordinal modified Rankin Scale (mRS) at 21 days after stroke onset</measure>
    <time_frame>21 days</time_frame>
    <description>The modified Rankin Scale scale is used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with excellent recovery (mRS score 0-1) at 3 months after stroke onset</measure>
    <time_frame>3 months</time_frame>
    <description>The modified Rankin Scale scale is used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with functional independence (mRS score 0-2) at 3 months after stroke onset</measure>
    <time_frame>3 months</time_frame>
    <description>The modified Rankin Scale scale is used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6, running from perfect health without symptoms to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ordinal MoCA at 3 months after stroke</measure>
    <time_frame>3 months</time_frame>
    <description>The Montreal Cognitive Assessment (MoCA) is a widely used screening assessment for detecting cognitive impairment. The MoCA test is a one-page 30-point test administered in approximately 10 minutes. MoCA scores range between 0 and 30. A score of 26 or over is considered to be normal.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Cerebrolysin and standard stroke care</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard stroke care</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerebrolysin</intervention_name>
    <description>Dosage, frequency, duration and mode of administration of Cerebrolysin follow the local hospital practice in accordance with the terms of the local marketing authorization and is not amended or influenced by the study. Prescribed Cerebrolysin will be used as solution for injection/concentrate for solution for infusion.</description>
    <arm_group_label>Cerebrolysin and standard stroke care</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with moderate to severe neurological deficits after acute ischemic stroke (NIHSS
        8-15) at baseline
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent

          -  Clinical diagnosis of acute ischemic stroke confirmed by imaging

          -  Moderate to severe neurological deficits with NIH Stroke Scale (NIHSS) 8 to 15, both
             inclusive

          -  No prior stroke

          -  No prior disability

          -  Patient's independence prior to stroke onset (pre-morbid mRS of 0 or 1)

          -  Reasonable expectation of successful follow-up (max. 100 days)

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Brainin, Univ.-Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Danube University Krems - Head of the Department for Clinical Neuroscience and Preventive Medicine / Head of the Center for Neurosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion Jech, Dr</last_name>
    <phone>+43 7665 20555</phone>
    <phone_ext>416</phone_ext>
    <email>marion.jech@everpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Winter, Dr</last_name>
    <phone>+43 7665 20555</phone>
    <phone_ext>422</phone_ext>
    <email>stefan.winter@everpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universit채tsklinik Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Kiechl, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kepler Universit채tsklinikum</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milan Vosko, Dr., PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CDK Salzburg, Universit채tsklinik f체r Neurologie</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johannes Mutzenbach, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2018</study_first_submitted>
  <study_first_submitted_qc>March 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute ischemic stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrolysin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

